. Author manuscript; available in PMC: 2023 Jan 23.

Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2022 Apr 16;180:102428. doi: 10.1016/j.plefa.2022.102428

Table 1.

Psoriasis Patient Characteristics by Treatment Group.

Characteristics	No Treatment (n = 10)	Atorvastatin (n = 20)	p-value
Age, y	35 (28 – 37)	44 (32 – 52)	0.16
Male sex,%	5 (50)	9 (45)	0.80
Body mass index, kg/m²	28 ± 6	28 ± 7	0.97
Systolic blood pressure	121 ± 10	127 ± 17	0.40
Diastolic blood pressure	75 ± 6	76 ± 12	0.87
Psoriasis
Psoriasis PASI score,	5.6 (3.2 – 19)	4.0 (3.6 – 6.9)	0.69
Psoriatic arthritis	3 (15)	4 (40)	0.13
Biologic therapy,%	4 (40)	14 (70)	0.11
Lipids
Total Cholesterol, mg/dL	179 (178 – 186)	182 (162 – 216)	0.79
Triglyercides, mg/dL	83 (58 – 150)	85 (61 – 104)	0.98
LDL-C, mg/dL	111 (110 – 121)	108 (83 – 131)	0.20
HDL-C, mg/dL	45 (43 – 52)	56 (46 – 63)	0.07

Data are mean ± SD, Median (IQR), or n (%). HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; PASI Score, psoriasis area severity index.